Recurrent Pneumonitis Induced by Atezolizumab (Anti-Programmed Death Ligand 1) in NSCLC Patients Who Previously Experienced Anti-Programmed Death 1 Immunotherapy-Related Pneumonitis
Hsu, P-Chih.; Li, S-Hong.; Yang, C-Ta.
Journal of thoracic oncology official publication of the International Association for the Study of Lung Cancer 13(11): e227-e230
2018
ISSN/ISBN: 1556-0864 PMID: 30368415 DOI: 10.1016/j.jtho.2018.06.022
Accession: 065899937
Full Text Article emailed within 0-6 h: $19.90
Related References
Naidoo, J.; Wang, X.; Woo, K.M.; Iyriboz, T.; Halpenny, D.; Cunningham, J.; Chaft, J.E.; Segal, N.H.; Callahan, M.K.; Lesokhin, A.M.; Rosenberg, J.; Voss, M.H.; Rudin, C.M.; Rizvi, H.; Hou, X.; Rodriguez, K.; Albano, M.; Gordon, R-Ann.; Leduc, C.; Rekhtman, N.; Harris, B.; Menzies, A.M.; Guminski, A.D.; Carlino, M.S.; Kong, B.Y.; Wolchok, J.D.; Postow, M.A.; Long, G.V.; Hellmann, M.D. 2017: Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 35(7): 709-717Bernard-Tessier, A.; Baldini, C.; Martin, P.; Champiat, Séphane.; Hollebecque, A.; Postel-Vinay, S.; Varga, A.; Bahleda, R.; Gazzah, A.; Michot, J-Marie.; Ribrag, V.; Armand, J-Pierre.; Marabelle, Aélien.; Soria, J-Charles.; Massard, C. 2018: Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression European Journal of Cancer 101: 160-164
Nishino, M.; Hatabu, H. 2017: Programmed Death-1/Programmed Death Ligand-1 Inhibitor-Related Pneumonitis and Radiographic Patterns Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 35(14): 1628-1629
Yu, N.Y.; Deftos, M.; Wang, C.C. 2018: Pneumonitis in Combined Anti-programmed Death-1 Immunotherapy and Radiation Therapy for Renal Cell Carcinoma Cureus 10(12): E3748
Rivera, N.; Boada, A.; Bielsa, M.Isabel.; Fernández-Figueras, M.Teresa.; Carcereny, E.; Moran, M.Teresa.; Ferrándiz, C. 2017: Hair Repigmentation During Immunotherapy Treatment With an Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Agent for Lung Cancer JAMA Dermatology 153(11): 1162-1165
Shi, V.J.; Rodic, N.; Gettinger, S.; Leventhal, J.S.; Neckman, J.P.; Girardi, M.; Bosenberg, M.; Choi, J.N. 2016: Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy JAMA Dermatology 152(10): 1128-1136
Khunger, M.; Rakshit, S.; Pasupuleti, V.; Hernandez, A.V.; Mazzone, P.; Stevenson, J.; Pennell, N.A.; Velcheti, V. 2017: Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials Chest 152(2): 271-281
Cui, P-Fei.; Ma, J-Xun.; Wang, F-Xue.; Zhang, J.; Tao, H-Tao.; Hu, Y. 2017: Pneumonitis and pneumonitis-related death in cancer patients treated with programmed cell death-1 inhibitors: a systematic review and meta-analysis Therapeutics and Clinical Risk Management 13: 1259-1271
Le Burel, Sébastien.; Champiat, Séphane.; Mateus, C.; Marabelle, Aélien.; Michot, J-Marie.; Robert, C.; Belkhir, R.; Soria, J-Charles.; Laghouati, S.; Voisin, A-Laure.; Fain, O.; Mékinian, Aène.; Coutte, L.; Szwebel, T-Anne.; Dunogeant, L.; Lioger, B.; Luxembourger, Cécile.; Mariette, X.; Lambotte, O. 2017: Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis European Journal of Cancer 82: 34-44
Fukuda, M.; Yamaguchi, H.; Mukae, H.; Ashizawa, K. 2018: Programmed death ligand-1 inhibitors potentially carry a lower risk of pneumonitis compared with programmed death-1 inhibitors in patients with non-small cell lung cancer Journal of Thoracic Disease 10(Suppl. 33): S4082-S4084
Bernard-Tessier, A.; Jeanville, P.; Champiat, Séphane.; Lazarovici, J.; Voisin, A-Laure.; Mateus, C.; Lambotte, O.; Annereau, M.; Michot, J-Marie. 2017: Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies European Journal of Cancer 81: 135-137
Santoni, M.; Conti, A.; Buti, S.; Bersanelli, M.; Foghini, L.; Piva, F.; Giulietti, M.; Lusuardi, L.; Battelli, N. 2018: Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis ImmunoTherapy 10(15): 1303-1313
Nie, R-Cong.; Chen, F-Ping.; Yuan, S-Qiang.; Luo, Y-Shan.; Chen, S.; Chen, Y-Ming.; Chen, X-Jiang.; Chen, Y-Bo.; Li, Y-Fang.; Zhou, Z-Wei. 2019: Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials European Journal of Cancer 106: 1-11
Ilie, M.; Juco, J.; Huang, L.; Hofman, V.; Khambata-Ford, S.; Hofman, P. 2018: Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients Cancer Cytopathology 126(4): 264-274
Rizvi, H.; Sanchez-Vega, F.; La, K.; Chatila, W.; Jonsson, P.; Halpenny, D.; Plodkowski, A.; Long, N.; Sauter, J.L.; Rekhtman, N.; Hollmann, T.; Schalper, K.A.; Gainor, J.F.; Shen, R.; Ni, A.; Arbour, K.C.; Merghoub, T.; Wolchok, J.; Snyder, A.; Chaft, J.E.; Kris, M.G.; Rudin, C.M.; Socci, N.D.; Berger, M.F.; Taylor, B.S.; Zehir, A.; Solit, D.B.; Arcila, M.E.; Ladanyi, M.; Riely, G.J.; Schultz, N.; Hellmann, M.D. 2018: Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 36(7): 633-641
Shen, J.; Chang, J.; Mendenhall, M.; Cherry, G.; Goldman, J.W.; Kulkarni, R.P. 2018: Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management Therapeutic Advances in Medical Oncology 10: 1758834017751634
Hamid, O.; Carvajal, R.D. 2013: Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy Expert Opinion on Biological Therapy 13(6): 847-861
Rosenberg, J.E.; O'Donnell, P.H.; Balar, A.V.; McGregor, B.A.; Heath, E.I.; Yu, E.Y.; Galsky, M.D.; Hahn, N.M.; Gartner, E.M.; Pinelli, J.M.; Liang, S-Ying.; Melhem-Bertrandt, A.; Petrylak, D.P. 2019: Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 37(29): 2592-2600
Chakravarti, N.; Prieto, V.G. 2015: Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis Translational Lung Cancer Research 4(6): 743-751
Viteri, S.; González-Cao, Mía.; Barrón, F.; Riso, A.; Rosell, R. 2015: Results of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancer Translational Lung Cancer Research 4(6): 756-762